ARGX - ア―ジェンクスSE （argenx SE） ア―ジェンクスSEARGXのチャート
ARGXの企業情報
| symbol | ARGx |
|---|---|
| 会社名 | argenx SE （ア―ジェンクスSE） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アルジェン(argenx SE)(旧名: arGEN X BV)はオランダに本拠を置くバイオ医薬品会社である。同社はラマ免疫系の特徴を利用する発見プラットフォームであるSimple Antibodyを用いて、分化した抗体治療薬のパイプラインを製造・開発する。同社はがん及び自己免疫適応に重点を置いた抗体治療薬のパイプラインを開発する。そのパイプラインは細胞増殖・生存などの腫瘍の機能を調節するヘム悪性腫瘍及び固形腫瘍のための抗体であるARGX-110、複数の固形腫瘍における細胞増殖、血管新生及び転移に関与する受容体チロシンキナーゼであるc-MetのアンタゴニストのARGX-111、並びにそれらの共通の受容体の遮断によるシグナル伝達を媒介されるIL-20及びIL-22（インターロイキン）の中和により、アトピー性皮膚炎を標的とする抗原であるARGX-112を含む。 ア―ジェンクスSEはオランダのバイオ医薬品企業。臨床ステ―ジで、主にがんと自己免疫病の治療薬の開発・商品化に従事する。新規の発見・開発に取り組むと同時に、既知の治療法に対する研究も進める。同社臨床パイプラインは抗体エンジニアリングと同社「Simple Antibody」プラットフォ―ムはラマ免疫系の治療法などを含む。本社所在地はブレダ。 Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. |
| 本社所在地 | Willemstraat 5 Breda 4811 AH NLD |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 39539 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 73人 |
| url | www.argenx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/argx |
| adr_tso | 18157259 |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 70.795 |
| 時価総額（marketcap） | 1285443150.905 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
ARGXのテクニカル分析
ARGXのニュース
Argenx stock dips as FDA extends review period for subcutaneous efgartigimod 2023/01/27 10:50:09 Seeking Alpha
Argenx (ARGX) said that the U.S. Food and Drug Administration ((FDA)) extended the review of its application seeking approval of subcutaneous ((SC)) efgartigimod to treat adult…
argenx: Trigger Ready, But Waiting For Stronger Earnings Profile 2023/01/26 16:00:00 Seeking Alpha
Argenx caught a strong bid in FY22'' on the back of advancements in its Efgartigimod [Vyvgart] pipeline for Myasthenia Gravis. Read more here.
Argenx reports preliminary FY22 global net sales of Vyvgart 2023/01/09 17:18:29 Seeking Alpha
Argenx (ARGX) said preliminary full-year 2022 global net sales of Vyvgart amounted to $402M.For Q4, preliminary global net sales of Vyvgart (efgartigimod alfa-fcab), which is used to…
Immunovant Stock: Initiating With A Buy Rating (NASDAQ:IMVT) 2023/01/08 13:47:20 Seeking Alpha
Immunovant is developing a similar drug to argenx, but at 10% of argenx’s valuation. Read more to see the growth catalysts, risks and why I consider it a buy now.
Morgan Stanley Positive on argenx SE , ''Catalyst Driven Idea: CIDP Topline Readout'' 2023/01/05 21:16:02 Investing.com
https://www.investing.com/news/pro/morgan-stanley-positive-on-argenx-se--catalyst-driven-idea-cidp-topline-readout-432SI-2974196
argenx SE PT Raised to EUR425 at Deutsche Bank 2022/09/22 07:48:10 Investing.com
https://www.investing.com/news/pro/argenx-se-pt-raised-to-eur425-at-deutsche-bank-432SI-2896883
Argenx files for US approval of subcutaneous form of neuromuscular disorder drug 2022/09/21 09:50:24 Seeking Alpha
Argenx (ARGX) submitted an application to the U.S. Food and Drug Administration ((FDA)) seeking approval of subcutaneous ((SC)) efgartigimod to treat adult patients…
Should You Consider Investing in Argenx SE (ARGX)? 2022/09/10 03:22:30 Insider Monkey
Baron Funds, an asset management firm, published its “Baron Durable Advantage Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. Baron Durable Advantage Fund (the “Fund”) declined 15.7% (Institutional Shares) during the second quarter, roughly in line with the 16.1% decline for the S&P 500 Index (the “Index”), the […]
argenx SE PT Raised to $465 at Piper Sandler 2022/08/26 10:43:18 Investing.com
https://www.investing.com/news/pro/argenx-se-pt-raised-to-465-at-piper-sandler-432SI-2880763
Futures Rise In Morbid Volumes With All Eyes On 50% Fib Retracement Level 2022/08/12 12:08:08 Zero Hedge
Futures Rise In Morbid Volumes With All Eyes On 50% Fib Retracement Level European stocks and US futures rallied on the last day of the week, however traded well off session highs in extremely low-volume trading and tracked the sudden drop in oil, as investors pressed bets that easing inflation will allow the Fed to pivot to less aggressive rate hiking (if not ease outright). S&P 500 and Nasdaq 100 contracts rose about 0.3%, with both underlying indexes set to post their longest sequence of weekly gains since November. Treasury yields were steady at 2.87% and the US dollar rose but was set for the worst week since May. Crude oil fell, reducing its biggest weekly gain in about four months. Gold headed for a fourth weekly gain and Bitcoin was summarily smacked down below the $24,000 level yet again as crypto bears fight to preserve the upper hand. For the second day in a row an attempt to void the bear market rally narrative by pushing spoos above the 50% fib retracement level is being defended by bears, with futures trading at 4222, or right on top of the critical level, which also doubles as the 100DMA.
argenx SE PT Raised to EUR425 at Deutsche Bank 2022/09/22 07:48:10 Investing.com
https://www.investing.com/news/pro/argenx-se-pt-raised-to-eur425-at-deutsche-bank-432SI-2896883
Argenx files for US approval of subcutaneous form of neuromuscular disorder drug 2022/09/21 09:50:24 Seeking Alpha
Argenx (ARGX) submitted an application to the U.S. Food and Drug Administration ((FDA)) seeking approval of subcutaneous ((SC)) efgartigimod to treat adult patients…
Should You Consider Investing in Argenx SE (ARGX)? 2022/09/10 03:22:30 Insider Monkey
Baron Funds, an asset management firm, published its “Baron Durable Advantage Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. Baron Durable Advantage Fund (the “Fund”) declined 15.7% (Institutional Shares) during the second quarter, roughly in line with the 16.1% decline for the S&P 500 Index (the “Index”), the […]
argenx SE PT Raised to $465 at Piper Sandler 2022/08/26 10:43:18 Investing.com
https://www.investing.com/news/pro/argenx-se-pt-raised-to-465-at-piper-sandler-432SI-2880763
Futures Rise In Morbid Volumes With All Eyes On 50% Fib Retracement Level 2022/08/12 12:08:08 Zero Hedge
Futures Rise In Morbid Volumes With All Eyes On 50% Fib Retracement Level European stocks and US futures rallied on the last day of the week, however traded well off session highs in extremely low-volume trading and tracked the sudden drop in oil, as investors pressed bets that easing inflation will allow the Fed to pivot to less aggressive rate hiking (if not ease outright). S&P 500 and Nasdaq 100 contracts rose about 0.3%, with both underlying indexes set to post their longest sequence of weekly gains since November. Treasury yields were steady at 2.87% and the US dollar rose but was set for the worst week since May. Crude oil fell, reducing its biggest weekly gain in about four months. Gold headed for a fourth weekly gain and Bitcoin was summarily smacked down below the $24,000 level yet again as crypto bears fight to preserve the upper hand. For the second day in a row an attempt to void the bear market rally narrative by pushing spoos above the 50% fib retracement level is being defended by bears, with futures trading at 4222, or right on top of the critical level, which also doubles as the 100DMA.